Saturday, November 17, 2018 1:07:28 PM
With the data for M281 and M254 not due out until 2020, the only obvious near-term events for Momenta are finding a partner for M923 and a resolution of its partnership with Mylan. There's also the possibility of out-licensing M281 and M254, but Momenta would be able to get a better price if it waits until it generates the data, so a secondary offering may end up being the best choice for shareholders even though it'll result in some dilution.
Momenta Moves On
Brian Orelli (TMFBiologyFool)
Nov 16, 2018
Read more:
https://www.fool.com/investing/2018/11/16/momenta-moves-on.aspx
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM